India, June 24 -- uniQure N.V. (QURE), a healthcare company, priced its previously announced public offering, which has been upsized to approximately $225 million in gross proceeds. The offering of 4.95 million shares was priced at $45.50 per share. The offering is expected to close on or about June 25, 2026.
In addition, uniQure has granted the underwriters a 30-day option to purchase up to 0.74 million additional shares at the public offering price.
H.C. Wainwright & Co. is acting as lead manager for the offering.
The company's lead investigational candidate is AMT-130, a gene therapy candidate for the treatment of Huntington's disease.
googletag.cmd.push(function() { googletag.display('div-gpt-ad-1568189509843-0'); });
QURE has trad...